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Abstract

Background
A growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease (RED).

Methods
The study was in two parts: an electronic questionnaire sent to UK neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective multi-centre observational study of current neurosurgical oncology practice. 

Results
Twenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data was collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. RED was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for RED. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit.

Conclusion
There is a subset of patients in which GTR is thought possible but not achieved at surgery, which, if resected early may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of RED/GTR and examine the potential benefit of this early re-intervention. 
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Introduction
Glioblastoma (GB) is the most common and most malignant primary brain tumour in adults, with over 20 years of life lost per patient 1. Survival trends for patients with CNS malignancies have remained largely static 2. Despite optimal treatment the median survival for such patients is still only 14-24 months with a two-year survival of 26.5% 3,4 and a five-year survival of approximately 10% 5 .The current gold standard of treatment involves gross total resection (GTR) followed by concurrent radiotherapy and chemotherapy with temozolomide and subsequent adjuvant temozolomide chemotherapy 4. GTR is defined by complete resection of contrast enhancing tumour on a contrast-enhanced T1-weighted postoperative magnetic resonance imaging (MRI) scan performed within 72 hours of surgery 6.   

GB is an intrinsic brain tumour, infiltrating normal brain tissue. Microscopically there is no distinct tumour/brain interface and radical resection risks causing permanent neurological deficit, worsening prognosis 7,8. In fact, in some patients GTR is not possible, because of the eloquent location and multi-focal distribution of the tumour. Nevertheless, the importance of obtaining a gross total resection where possible is increasingly recognized 3,9–23 and is being incorporated into European guidelines for the management of patients with GB 24,25. Some surgical studies suggest that there is a stepwise increase in survival with extent of resection (EoR) from a threshold of 78-80% 23,26 up to 95-100%. Other studies suggest that removal of all contrast enhancing disease is necessary 12,27 or that supra-maximal resection of GB may provide further survival benefit 10,28,29. A recent meta-analysis of 37 studies (41117 patients with newly diagnosed GB) concluded that GTR “substantially improves overall and progression-free survival” but added that “the quality of the supporting evidence is moderate to low” 30. 

The opportunity for awake tumour surgery to identify and preserve eloquent function, along with advances such as 5-ALA that accumulates in tumours, and intra-operative MRI, have improved the neurosurgeons ability to maximise the extent of surgical resection. Despite the use of operative adjuncts in cases where GTR is the expressed preoperative aim, there are circumstances where GTR is not achieved 31,32. In some cases this may reflect changing surgical priorities, for example in the context of bleeding, but in other cases it may be unintentional. In these patients there may be prognostic benefit from re-operating on the residual enhancing disease (RED). This will also have risks, but there is some preliminary evidence to suggest that it is safe 33.

The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease in patients with suspected GB. We report the results of a service evaluation of practice in the United Kingdom to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease in patients deemed suitable for GTR. The study was conducted in two parts: (1) an electronic questionnaire to neuro-oncology surgeons and (2) a 3-month prospective multi-centre observational study of current neuro-oncological practice, both in the UK. 

Methods
Study design – Questionnaire 
An electronic questionnaire was sent to UK neuro-oncology surgeons to assess surgical practice including the throughput of tumour patients and the numbers deemed suitable for GTR (supplementary file). There were also questions regarding access to surgical adjuncts such as 5-ALA, awake surgery, and attitudes towards contributing to a randomised control trial investigating early repeat operation. 

Study design – Prospective cohort study
The second part of the study was a prospectively collected multi-centre observational study on current neuro-oncological practice.  

Patient Selection
Patients with suspected GB that were scheduled to undergo GTR at first surgery following discussion at a multi-disciplinary meeting (MDT) between 01/05/2016 and 31/07/2016 were eligible for inclusion. Patients were identified prospectively at MDT meetings and data was collected prospectively during their subsequent inpatient stay. Inclusion criteria included adult patients (age >18) with suspected GB on presenting magnetic resonance imaging (MRI) scan and MDT decision that the tumour was suitable for GTR. Exclusion criteria included children (age <18) with subsequent histology that confirmed an alternative diagnosis. Patients with recurrent tumours were included in the study provided GTR was the aim at surgery.

Data Collection
Data on patient demographics, tumour location, surgical adjuncts, residual disease intraoperative/postoperative MRI as well as adjuvant treatment and complications (Supplementary data) was collected through the British Neurosurgery Trainees Research Collaborative (BNTRC). As with previous models of research performed by the BNTRC 34, each neurosurgical unit had a trainee principal investigator and a consultant principal investigator. Data was collected locally and then collated centrally after the end of the study period. Data was analysed in Microsoft Excel (2011) and IBM ® SPSS Statistics ® (version 24) . 

Ethics
This project was registered, approved and recorded at each local unit by their local Research and Audit departments.

Results
Surgical Practice
There were responses from 27 neuro-oncology surgeons from 22/38 neurosurgical units in the UK, who estimated a total of ~3000 operations for newly diagnosed GB per year, of which roughly 1800 (60%) were amenable for GTR. 24/27 (88.9%) of responders said >90% of patients were discussed at MDT before surgery.

With regards to surgical adjuncts, 100% of surgeons had access to intraoperative neuro-navigation. 44.4% of surgeons said they had routine access to 5-ALA with a further 29.6% of surgeons having limited access for specific cases and 25.9% of surgeons having no access to 5-ALA. 17/27 (63%) of surgeons said they routinely used awake surgery with bipolar stimulation where indicated, with 16/27 (59.3%) using speech and language testing and 4/27 (14.8%) using electromyography recordings under general anaesthetic.

The majority of surgeons (24/27, 88.9%) were able to obtain a MRI within 72 hours of surgery routinely, with only 1 surgeon unable to obtain postoperative MRI imaging. Most surgeons estimated there to be 11-20 patients per annum who were deemed suitable for GTR, but who had RED on their post operative scan (9/27, 33.3%), followed by 5-10 patients in 6 (22.2%) of surgeons with 4 (14.8%) surgeons estimating over 20 cases per annum.

Service Evaluation
We prospectively collected data on 113 patients from 15 neurosurgical centres (range 1 – 26 patients per centre) with a mean age of 58.2 (range 28-85) and a male:female ratio of (73:40). Table 1 highlights the demographic information of the cohort of patients included in the study. Most patients were independently functioning at presentation with 91 patients (80.5%) classified as World Health Organisation (WHO) Performance Score (PS) 0 or 1 (table 1). 89 patients (78.7%) had at least once comorbidity (table 1). The most common presenting symptom/sign was headaches (44/113, 38.9%) followed by focal neurological deficit (40/113, 35.3%) (table 1).  The intracerebral distribution of tumours can be seen in table 1.

There was varying practice in the use of intraoperative surgical adjuncts, illustrated in table 2. 5-ALA was the most commonly used adjunct, being used in 18 (15.9%) of cases followed by awake surgery (14, 12.4%) and intraoperative ultrasound (14, 12,4%). There was little use of iMRI (4, 3.5%), reflecting the small number of centres with access to this technology in the UK. 

Postoperative complications were seen in 27 (23.6%) patients (table 2), of which the majority were medical complications (6/27) or miscellaneous (8/27). Other complications included worsening cognition, hydrocephalus, new focal neurological deficit, bowel perforation and rapid clinical decline.

In 91/111 (82.0%) cases the operating surgeon felt that GTR was achieved at the time of surgery. Reasons for residual disease at the time of surgery were: tumour adherent to vessels (2.7%), eloquent brain (5.4%), cardiac instability (0.9%), unknown (7.2%). 

After surgery 80 patients (70.8%) had a MRI scan within 72hours. In marked contrast to the operating surgeon’s perception the imaging data confirmed 44 patients (55%) had RED on their postoperative scan. This RED was deemed operable in 13 cases (16.3%). Surgeon estimation of GTR at time of surgery was similar whether 5-ALA (88.9% c.f. 80.6%, Fisher’s exact test, p=0.52) or any surgical adjunct (87.2% c.f. 78.1%, Fisher’s exact test, p=0.32) was used when compared to when the adjuncts were not used. However, the rate of GTR seen on post-operative MRI was trending towards significance when 5-ALA was used (76.5% c.f. 49.2%, Fisher’s exact test, p=0.057) and was significant when all adjuncts were taken into account (71.9% c.f. 43.8%, Fisher’s exact test, p=0.021). This would support the use of surgical adjuncts to increase GTR rates.

No patient had a repeat debulking within 1 week of primary surgery. Reasons for non-operation include perceived lack of clinical benefit (5/13), medical comorbidities/poor PS (2/13) and disagreement between surgeon and radiologist about whether there was RED (2/13) and unknown (4/13). In the two cases of disagreement, the surgeons perceived GTR at the time of surgery and the small amount of RED left was thought to not represent tumour but post surgical changes/surgical haemostatic agents used intraoperatively.

Discussion
This study highlights varying practices amongst neurosurgical units in the UK in the approach to resection of suspected GB amenable to GTR. This likely represents the wide variety of surgical techniques available and a lack of consensus over the best surgical practice. In addition, financial restraints may restrict the access to investigations and equipment such as postoperative MRI scans within 72 hours of surgery and intraoperative surgical adjuncts. It is encouraging that over 70% of patients now receive a postoperative MRI as baseline for identification of residual disease in order to plan adjuvant therapy. Our survey also demonstrates that the utilisation of surgical adjuncts to maximise the extent of surgical resection is low. This may reflect cost pressures in the publically funded National Health Service, but the 15.9% of patients who had 5-ALA used in their surgery contrasts to the 44.4% of surgeons who reported routine access to 5-ALA in the questionnaire. Consistent with these observations we note that while 22 units responded to the questionnaire, only 15 units participated in the survey. So it is likely that our data under-represents the true incidence of RED and may over-represent the extent to which advanced surgical adjuncts are used.

The lack of utilization of surgical adjuncts is a concern when a significant proportion of patients have postoperative RED even where GTR was thought possible pre-operatively. Identifying the enhancing tumour margin intra-operatively with only microscopy and image guidance can be challenging, as evidenced by only 30-40% of operations achieving maximal resection when these traditional methods were used 6.  The failure to achieve GTR in our study cohort is underlined by the discrepancy between the perceived rate of GTR at the time of surgery and the actual rate of GTR on the postoperative scan (82% c.f. 55%), reflecting the difficulty identifying the tumour margins. This is not a new phenomenon, and reports demonstrate that surgeons ability to judge GTR at the time of surgery is only correct in approximately one third of cases 31,32.  Newer techniques, such as iMRI, 5-ALA and awake surgery are reported to facilitate surgeons in achieving doubling of GTR rates to over 65% in selected patients 6,11,16,35,36. The failure to achieve GTR may also reflect a failure to correctly assess whether GTR was possible. 

16.3% of patients in our study had RED that was thought amenable to early repeat resection before adjuvant therapy, but no patient went back to surgery. Early re-operation to remove RED in patients with GB before further treatment has been shown to be feasible without increased morbidity 33. However, in that study only a low proportion (6%) of patients underwent early re-intervention.

GTR as a predictor of outcome does not necessarily imply that early revision surgery would be of benefit. There is very little data looking at whether rapid reoperation to resect RED will improve clinical outcome to the same level as patients in whom GTR was achieved at first surgery. One worry about repeat surgery is that whilst it may offer a theoretical survival advantage by reducing the tumour load, the potential delay to radiotherapy may impact negatively on survival. There have been numerous studies looking at the relationship between timing of radiotherapy and survival, with some showing a beneficial effect of early radiotherapy37, whilst others suggested no impact of timing as long as it is commenced within a 6 week window 38. One study even showed a beneficial effect of waiting at least 4 weeks postoperatively 39. Encouragingly, a recent meta-analysis of 8716 GB patients has found no difference in overall survival (OS) related to the time to radiotherapy 40. If this is the case then that early reoperation may not negatively impact on survival through delay to radiotherapy. However, there are other factors that must be considered when deciding on early revision surgery. These include prolonged hospital stay and immobilization for a second operation with their inherent risk of venous thrombo-embolic disease as well as increased risk of infection both surgical and anaesthesia related. There are also psychological and social factors that become important when discussing a second large operation in a short space of time that patients and carers may not be prepared for. Although feasible on a small scale33, these factors need to be taken into account when up-scaling this practice. 

The most common reason UK surgeons gave for not undertaking this early surgery was a lack of perceived clinical benefit (38.4%) despite a growing body of evidence to suggest GTR is an independent positive prognostic factor (Watts & Sanai 2016 and Table 3). Maximally reductive surgery not only increases survival independently, but also increases the effectiveness of adjuvant therapies 41. 

If the data favours maximal resection of tumours where possible, debate exists over the minimum EoR that is associated with maximal survival benefit. Studies have historically classified EoR into 3 or 4 categories: gross total resection (GTR), near total resection (NTR), subtotal resection (STR) and partial resection (PR). Apart from GTR, which is classified as the complete removal of contrast enhancing disease on a postoperative MRI performed within 72 hours, the definition of the other categories is variable and subjective in nature, making it difficult to incorporate into clinical management protocols, or indeed to compare studies 17,20,22,42–44. 

Quantification of residual tumour volumes can produce more accurate data on EoR and RED. Lacroix et al. published a volumetric series looking at patients undergoing resection for GB. They reported that a minimum EoR of 89% was required to achieve any benefit in survival from surgery with incremental benefit from further resection up to a maximum of 4.2 months with 98% resection 23. This was followed by a study by Sanai et al. that found a survival difference in a dichotomised cohort with EoR values of 78% or above but a clinically meaningful survival difference of 3.8% only in patients EoR values at or above 95%. They conclude that “whereas the 78% threshold represents the minimum value at which a survival benefit is seen, [recursive partition analysis] selected 95% as the most significant predictor of survival in patients with GB, emphasizing the added value of a complete resection”26. A common interpretation of these data is that an EoR as low as 78% is sufficient to yield a clinically meaningful survival benefit. However, analysis of recent clinical data suggests that “complete” resection (defined as the absence of RED on post-operative MRI) provides optimal clinical benefit. For example in a trial of Enzasturin patients with GB who had GTR on their baseline post-op MRI had enhanced PFS-6 (progression-free survival at 6 months) 45. In EORTC 26071-22072 (CENTRIC) GTR conveyed a 6.6 month survival advantage in the experimental arm (30.4 vs 24.8 month) and 10.7 month survival advantage in the control arm (34.3 vs 23.6 month).46. In the DIRECTOR trial (NCT00941460) complete resection of contrast-enhancing tumor volume was associated with improved survival in recurrent glioblastoma12.

As the present study did not assess resection volumes or, indeed, the volume or location of RED, the lack of early reoperation, of which 38.4% of cases were due to lack of perceived clinical benefit, must be interpreted with caution. Future studies should take into account the volume, location and distribution of RED as these will likely have implications on the risk-benefit balance of early reoperation for RED. 

Conclusion and Future Directions

This study is the first to prospectively evaluate the current surgical management of GB patients in the UK who were judged suitable for radical surgery by the MDT. We show that there is wide variation in approaches to achieving GTR in the UK. Where RED occurs despite surgery there remains clinical doubt as to whether these patients would benefit from early revision surgery. Whilst there is a large volume of retrospective data to support the beneficial effects of maximal safe resection in patients with GB there is little prospective data and even less data on early reoperation to remove RED. Consequently relatively little is known about the impact of GTR on prognosis, morbidity and quality of life for patients. In order to develop and optimise surgical management protocols further prospective research is required to determine the clinical impact of RED and early re-intervention to convert STR to GTR.
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New/Recurrent GBM	Survival Benefit	Study	No. Patients	Maximum Survival advantage	Volumetric study	Minimum resection required
New 	Yes	Brown et al. 2016 30*	20,76920,699	16.1% 1yr survival10.3% 2yr survival	No	GTR
		Chaichana et al. 2014 (1)18	259	3.9 months	yes	70% or <5cm3 RTV
		Chaichana et al. 2014 (2)9	292	4.7 months (EoR) 4.2 Months (RTV)	Yes	95% or <2cm3 RTV
		Grabowski et al.14	128	4.5 months	Yes	98% or <2cm3 RTV
		Hollerhage et al.42	118		No	GTR
		Keles et al.	107	6.4 months	Yes	75%
		Kreth et al.22	273	5.4 months	no	GTR
		Kuhnt et al.13	88	5 months	yes	98%
		Lacroix et al.23	416	4.2 months	yes	89%
		Li et al. 10	1229	5.4 months + 5.2 months for addition FLAIR resection	Yes	100% +/- 53.2%additional FLAIR resection
		Local data	285	4 months	No	GTR
		Marko et al.47	721		Yes	Continuous relationship
		McGirt et al.17	451	2 months (GTR Vs NTR) 5 months (GTR Vs STR)	No	GTR
		Nitta et al.48	68	8 months	No	GTR
		Orringer et al.19	46	44% 1 year survival	yes	90%
		Roder et al.11	117	13% 6 month PFS	Yes	100%
		Salvati et al.20	105	3.5 months	no	GTR
		Sanai et al.26	500	3.8 months	Yes	78%
		Shibamoto et al.49	135	4 months	No	STR
		Simpson et al.43	645	0.9 months (GTR Vs STR) 4.7 months (GTR Vs Biopsy)	No	GTR
		Stark et al.50s	267		No	GTR
		Stummer et al. 200851	243	4.9 months	no	GTR
		Stummer et al. 20123	143	>7.1 months	No	residual tumour diameter <1.5cm
		Ushio et al.52	105	5.8 months	No	GTR
		Vecht et al.53	177	1 month	No	Extensive Surgery
	No	Coburger et al.16	33	No difference	Yes	
		Kowalczuk et al.54	52	No difference	No	
	 	Phillips et al.55	173	No difference	No	 
		Pope et al.56	110	No difference	Yes	
						
Recurrent	Yes	Bloch et al.57	107	3.4 months	Yes	95%
		McGirt et al.17	294	2 months (GTR Vs NTR) 6 months (GTR Vs STR)	No	GTR
		Oppenlander et al.58	170	10.8 months	Yes	80%
		Quick et al.59	40	6.7 months	Yes	100%
		Ringel et al.60	503	4.4 months	No	GTR
		Suchorska et al.12	71	6.4 months	Yes	100%
		Yong et al.15	97	7.5 months	Yes	<3cm3 RTV
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